Article

Angioedema Resolves with Omalizumab

Author(s):

It appears that 300 mg of omalizumab (Xolair/Genentech) is effective in reducing angioedema, according to the results of a new study.

It appears that 300 mg of omalizumab (Xolair/Genentech) is effective in reducing angioedema, according to the results of a new study.

Appearing in the October 2016 edition of the Annals of Allergy, Asthma and Immunology, the study was written by James Zazzali, PhD, MPH, of Genentech Inc., South San Francisco, CA, and colleagues.

Approximately 40% of patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) experience the acute swelling of subcutaneous tissue, or angioedema.

Non-sedating histamine 1, (H1) has been the only approved treatment for CIU/CSU, but does not provide relief of symptoms for many patients. Omalizumab, when used as an add-on therapy to H1-antihistamines appears to be effective in Phase 3 studies.

The study ASTERIA I, compared patients in randomized groups who received either 75 mg of omalizumab, 150 mg of omalizumab, 300 mg of omalizumab, or placebo. ASTERIA II was similar with patients receiving either 75 mg of omalizumab, 150 mg of omalizumab, 300 mg of omalizumab, or placebo. GLACIAL included groups receiving 300 mg of omalizumab or placebo.

In all three studies, 44%-53% of patients were experiencing angioedema at baseline, and had similar disease activity. The researchers report, “During the active treatment period, use of 300 mg of omalizumab resulted in a reduction in the percentage of patients with angioedema and a reduction in overall angioedema days.”

The authors point out that in this study, patients and not physicians, reported both angioedema and angioedema management. Severity was not assessed, nor was rescue medication controlled-for in this study.

“Treatment with 300 mg of omalizumab was efficacious in reducing patient-reported angioedema in patients with CIU/SCU who were symptomatic despite a variety of treatments,” conclude the researchers.

Related Coverage:

Omalizumab Highly Effective for Treatment of Chronic Spontaneous Urticaria

Atopic Dermatitis Yields to Asthma Medication

Multiple Food Allergies Can Be Treated at the Same Time Using Asthma Drug

Related Videos
Monica Kraft, MD: Discussing Phase 3b Findings on Albuterol/Budesonide for Asthma
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD
2 Helpful Clinical Tips for Dermatologists, with Eingun James Song, MD
What Are Some Other Methods To Manage Skin Cancer Outside of Biopsies?
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Christopher Bunick, MD, PhD: Facts About Systemic Therapies’ Safety, Mechanism of Action
© 2024 MJH Life Sciences

All rights reserved.